ESR1
Estrogen receptor mutations driving endocrine resistance in metastatic breast cancer. Targeted by elacestrant and emerging SERDs.
No Clinical Trials found for this biomarker.
Estrogen receptor mutations driving endocrine resistance in metastatic breast cancer. Targeted by elacestrant and emerging SERDs.
No Clinical Trials found for this biomarker.